MDG 1015
Alternative Names: MDG-1015Latest Information Update: 23 Dec 2024
At a glance
- Originator MediGene AG
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Dec 2024 Medigene submits clinical trial application (CTA) with European Medicines Agency (EMA) for MDG 1015 for Solid tumours
- 24 Oct 2024 Medigene plans the phase I EPITOME1015-I trial in Ovarian cancer, Adenocarcinoma, Liposarcoma and Synovial sarcoma (IV, Infusion) in USA in January 2025 (NCT06748872)
- 05 Sep 2024 Medigene submits IND application with US FDA for MDG 1015 in Solid tumors before September 2024